RxDoctor Payments Data

Meghan Jankowski

Gastroenterology · Boise, IDNPI 1518120179

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.0% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 51.4% of the total.

$1,972in general payments, 2019–2025

Across 113 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Bristol Myers Squibb$207
  • Takeda Pharmaceuticals U.S.A., Inc.$187
  • Sanofi$105
  • Johnson & Johnson$99
  • Pfizer$94
  • plus $266 from 8 others

What the payments were for

  • Food & beverage$1,87395%
  • Education$995%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,972 in reported general payments places this provider in the 55th percentile of 70 gastroenterology providers in Idaho.

See all gastroenterology providers in Idaho

Medicare billing

Part B allowed, 2024
$72,108
Medicare patients
356
Services billed
688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid25$230,724
Mesalamine31$15,166
MotegrityPrucalopride Succinate12$13,496
Omeprazole209$3,056
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl106$1,769
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl71$1,003
Colestipol Hcl11$968
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl44$718
Pantoprazole Sodium57$646
Famotidine25$579
Dicyclomine Hcl18$252
Esomeprazole Magnesium13$228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$56$230,72425 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$187$13,49612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 70 gastroenterology providers in Idaho.

Other gastroenterology in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →